New drug cocktail takes on deadly brain cancer
NCT ID NCT06630260
First seen Jan 22, 2026 · Last updated Jun 23, 2026 · Updated 26 times
Summary
This trial is testing two experimental drugs, avutometinib and defactinib, given together or with a standard chemotherapy (temozolomide) for people with high-grade brain tumours like glioblastoma. The study has two phases: first, to check safety and find the right dose, and second, to see if the drugs shrink tumours or delay progression. About 182 participants will be enrolled, focusing on those with specific genetic markers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA MULTIFORME (GBM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cambridge University Hospitals
RECRUITINGCambridge, CB2 0QQ, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Royal Marsden Hospital - Drug Development Unit
RECRUITINGSutton, SM2 5PT, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Royal Marsden Hospital - Neuro-Oncology Unit
RECRUITINGSutton, SM2 5PT, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
avutometinib and defactinib, with or without temozolomide
What this could lead to
If successful, this could point toward a new treatment option for aggressive brain tumours like glioblastoma, potentially slowing tumour growth or improving survival.
What could go wrong
This is an early phase 1/2 trial with a small number of participants, so the drugs may not prove effective or safe enough to move forward. Side effects from the combination therapy are unknown.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.